A new class
ability to bind the patient’s cancer cells
and induce cancer cell death while
avoiding effects on healthy tissue
the two strands and induces
Antigen Presenting Cells
stimulation through TLR9
T cells, leading to
tumor cell lysis
Tailoring the variable strand
to every patient
to generate 3D organoids
Personal drug assembly
New class of
Aummune’s lead program, AM003, has already initiated its Phase 1 clinical trial following successful demonstrations of efficacy and safety in multiple animal models. The company is now actively recruiting patients for this First-in-Human study, which targets those with locally advanced and metastatic solid tumors
Dr. Irit Carmi-Levy
PhD – GM, CSO & Founder
After joining Aummune in 2019 as Chief Scientific Officer, Dr Carmi-Levy has been serving as General Manager since June 2022.
She is a drug development expert and an immunologist by training, and served as a Project Director in BioLineR prior to joining Aummune. Dr Carmi-Levy completed her postdoctoral research at the Curie Institute and earned her PhD in Biochemistry and Molecular Biology from the Hebrew University.
Dr. Michelle Mahler
MD - CMO
Dr. Michelle Mahler is a Pediatric Hematologist Oncologist with experience in all stages of clinical drug development and is the Chief Medical Officer of Aummune and of 1E Therapeutics.
Prior to joining Aummune and 1E Therapeutics, she was the VP of clinical research and
development at C4Therapeutics, where she led the successful filing of INDs and initiation of their first in human oncology programs (Myeloma and Sarcoma).
Prior to C4 Therapeutics Michelle spent almost 10 years at Janssen R&D. During her time there she had multiple roles across all stages of drug development with increasing responsibility.
Highlights include leading registration studies in ibrutinib, submissions to the FDA and EMA, leadership in pediatric development, global launch work for Imbruvica, and commercialization, strategy and reimbursement activities in global medical affairs. Other activities of note included work in BARDA funded program (Radiation protectant) and due diligence activities, including clinical leadership (immune hematology) in the acquisition of Momenta pharmaceuticals by JNJ.
Prior to starting in industry Dr. Mahler trained in Pediatric Hematology and Oncology at Memorial Sloan Kettering Cancer Center and New York Presbyterian Hospital/ Weill Cornell, and General Pediatrics at Mount Sinai Medical Center in NY. Michelle obtained her medical degree from University of the Witwatersrand, South Africa.
Dr. Ido Bachelet
PhD - CTO & Founder
Dr. Bachelet is a recognized pioneer in therapeutic DNA nanotechnology and synthetic biology as well as a cofounder of multiple biotech and medical device companies including Sight Diagnostics, 1E Therapeutics and Wild Biotech. He holds a PhD in medical sciences from the Hebrew University, was a postdoctoral fellow at MIT and Harvard Medical School, and is the author of over 60 academic papers and patents.
Mr. Marius Nacht
Founder and investor
Mr. Nacht is a cofounder of a dozen tech and biotech companies and of multiple VC funds. He is also a direct investor in numerous companies and VC funds. In 1993, Mr. Nacht co-founded the cybersecurity firm Check Point Software Technologies (NASDAQ: CHKP) and held multiple executive roles as it went on to become a global pioneer in the cybersecurity industry. He recently stepped down from his position as chairman of Check Point to focus on his initiatives in the healthcare industry.
Mr. Nacht holds a BSc in Physics and Mathematics (cum laude) from the Hebrew University, and an MSc in Electrical Engineering and Communications Systems from Tel Aviv University. He is a graduate of the IDF elite Talpiot technological academy and a captain in the Israeli Air Force.
Dr. Uri Yaron
Dr. Yaron is a HealthTech and Life Sciences investment Executive who serves on multiple Boards. In his previous role he served as the WW President of Biosense Webster (BWI), a member of the Johnson & Johnson Family of Companies. Prior to his WW President role, Dr. Yaron has held several positions of increasing responsibilities in R&D, Business Development and General Management at Biosense Webster, Cordis, Cerenovus, Mentor, Acclarent, ASP & Sterilmed. Dr. Yaron holds a PhD in Physics from the Hebrew University of Jerusalem, summa cum laude. Prior to joining BWI, Dr. Yaron was a Member of the Technical Staff at the Micro-Physics Research Lab of AT&T Bell Laboratories. He is a co-author of over 40 peer-reviewed papers, including papers in Nature and Physical Review Letters, and the co-inventor of over 10 US patents. Dr. Yaron serves on the Board of Directors of the Western States of the American Heart Association. He was the Chairperson of the 2020 LA Heart & Stroke Walk. In addition, Dr. Yaron teaches an MBA course at the BioMed MBA Program of the Hebrew University, and coaches senior combat officers of the Israeli Defense Forces.
Dr. Karen Smith
Dr. Smith is a Biotech/Pharmaceutical Executive, Board Director and Clinical/Scientific Advisor. Her breadth of experience covers 100+ clinical trials and 20+ regulatory approvals in multiple jurisdictions including FDA, EMA, TGA, ANVISA, and PMDA; leading to product launches across diverse therapeutic areas including oncology (Herceptin, Vyxeos), rare disease (Defitelio), cardiology (Irbesartan), dermatology (Voluma, Botox, Aczone), neuroscience (Abilify, Solriamfetol), and anti-infectives (Teflaro). In addition to growth and creation of R&D pipelines, Dr. Smith’s successful record of business development includes acquisitions, divestitures, and partnership deals.
Dr. Smith has held various President, CEO, and Chief Medical Officer roles over the past 20 years. She has built companies from the ground up and is a strong advocate for women in science and diversity in the boardroom. Earlier in her career, she held senior leadership roles at Allergan, AstraZeneca and Bristol Myers Squibb. Dr. Smith currently serves on the Board of Antares (ATRS), Sangamo Tx (SGMO),and Capstan Tx. Previously, Dr. Smith served on the board of Forward Pharma A/S (FWD), Sucampo (SCMP), and Acceleron (XLRN), each with a greater than $1 billion exit.
Mr. Yuri D. Shoshan
Mr. Shoshan is and expert in early stage technology company building. He is currently the COO of 1E Therapeutics, and CEO of Augmanity, a private research lab. He was a Manager at McKinsey and Company and a Principal at Pitango VC, was the founding COO/CFO of BioLineRx, and served as CEO of Qualitas Health and a number of other early-stage medtech startups. Mr. Shoshan holds a BA in Economics and Mathematics from Columbia University and an MBA from the Harvard Business School.
Tel Aviv Medical Center (TAMC),
Sammy Ofer Building, Floor 10
Weizmann St 6, Tel Aviv-Yafo, ISRAEL